The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary toxicity data from the combination of pembrolizumab and definitive-dose radiotherapy for locally advanced head and neck cancer with contraindication to cisplatin therapy.
 
Jared Weiss
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; BioMarck Pharmaceuticals; Celgene; EMD Serono; Genentech; Inivata
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Celgene (Inst); Merck (Inst); novartis (Inst); Pfizer (Inst)
 
Jessica Ruth Bauman
No Relationships to Disclose
 
Allison Mary Deal
No Relationships to Disclose
 
Siddharth Sheth
No Relationships to Disclose
 
Bhishamjit S. Chera
No Relationships to Disclose
 
Colette Shen
No Relationships to Disclose
 
Chris Hilliard
No Relationships to Disclose
 
Tanguy Y. Seiwert
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Innate Pharma; Jounce Therapeutics; Lilly; Merck; Merck Serono
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
 
Ranee Mehra
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Innate Pharma
Research Funding - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Juneko E. Grilley-Olson
Research Funding - Genentech (Inst); MedImmune (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)